Tuberculosis is the leading cause of death from an infectious disease and a leading example of antimicrobial resistance. Carl Nathan of Weill Cornell Medicine will review the biology that frames the problem, the innovation gap that exacerbates it and the new work that qualifies TB drug discovery as an innovation engine.
What You Will Learn
- How the special challenges of TB that demand innovative solutions can advance drug discovery for other bacterial infections
- Why we must kill both replicating and non-replicating bacteria
- The importance of taking into account lesion-specific as well as systemic PK-PD as well as considering intrabacterial as well as host PK-PD
- Why we must extend the range of antibiotic targets and how to work in new collaborative structures
Co-producers
The Fine Print
ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.
;void(0);){kind=link}